Global Antibody Drug Conjugate (ADC) Growth Opportunities - Collaborations with Innovative Platform Developers will Drive Growth Potential

DUBLIN, Aug. 9, 2023 /PRNewswire/ -- The "Global Antibody Drug Conjugate (ADC) Growth Opportunities, Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

This research service overviews the global ADC market and provides a 6-year revenue forecast from 2023 to 2028.

An ADC comprises multiple components such as the antibody, conjugation chemistry, linker, and payload. Many companies are working on each component while others only develop ADCs, which makes the market highly competitive. The development of targeted delivery vehicles over standard antibodies is improving the performance of these drugs and expanding their potential for treating new cancers. New technologies are trying to address drawbacks of existing ADC technology, such as poor stability, leading to poor tolerability, efficacy, and a narrow therapeutic index and challenging ADC manufacturing.

This analysis shows that small and mid-sized enterprises that rely on contract development and manufacturing organizations (CDMOs)/contract research organizations (CROs) for initial drug development create novel antibody therapeutic technologies.

Many antibody developers have been decreasing in-house R&D efforts and increasing in-licensing or acquiring therapeutic antibody product lines to strengthen their pipelines. All major CDMOs are stepping up with new investments to support the next generation of ADC, making the segment more competitive. Biopharmaceutical companies are focusing on ADCs to reap the benefits of target specificity for selective tumor antigens. Developers are using robust approaches to improve payloads' potency as ADCs reflect the success rate in the last two years with seven approvals.

Report Scope:

• Market trends
• Leading disruptors
• Marketed and pipeline ADC that will drive growth in hematological and solid tumors
• Growth opportunities emerging from this space that stakeholders can leverage

Key Topics Covered:

1. Strategic Imperatives

• The Impact of the Top 3 Strategic Imperatives on the ADC Industry

2. Growth Environment

• Scope of Analysis
• ADC Market Highlights
• Growth Opportunities: The ADC Market
• Growth Drivers
• Growth Restraints
• Drug Conjugates' History, Progress, and Research Stages
• ADC Market Trends
• ADC Technology Evolution
• Precision Oncology Approaches for ADCs
• Biomarker Application Across the Cancer Continuum
• Life Cycle Management Strategies
• ADC Deals and Investment Outlook
• Notable ADC Partnerships and Collaborations, 2022 and 2023
• Approved ADCs: Hematological Cancer
• Approved ADCs: Solid Tumors
• Late-stage ADCs to Watch

3. Revenue Forecast and Analysis

• Forecast Assumptions
• Growth Metrics
• Revenue Forecast
• Solid Tumors (Launched)
• Solid Tumors (Pipeline)
• Hematological Cancer (Launched)
• Hematological Cancer (Late-stage Pipeline)

4. Companies to Action: ADC Market Disruptors

• Tubulis: Broad Spectrum of Technology Platforms
• LCB: Conjugation Technology Platforms
• Synaffix (Lonza): End-to-end ADC Services
• WuXi Biologics: ADC CRDMO
• Mersana Therapeutics: Late-stage ADC Pipeline and Platform
• Iksuda: A Toolbox Approach for ADC Development

5. Growth Opportunity Universe

• Growth Opportunity 1: ADC Combination Therapies for Precision Chemotherapeutics
• Growth Opportunity 2: Strategic Partnerships between CDMOs and Early-stage Platform and ADC Developers
• Growth Opportunity 3: Novel Linkers and Conjugation Chemistries

A selection of companies mentioned in this report includes

• Iksuda
• LCB
• Mersana Therapeutics
• Synaffix (Lonza)
• Tubulis
• WuXi Biologics

For more information about this report visit https://www.researchandmarkets.com/r/3uu4ax

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets